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Monoclonal antibodies directed to the epidermal growth factor receptor (EGFR) have a role in the management of
several solid tumors, alone or in combination with chemotherapy or radiation therapy. Recognized toxicities have
included hypersensitivity reactions, rash, hypomagnesemia, and constitutional symptoms, but the possibility that
the agents lead to immunosuppression or increase the risk of infection has only recently been recognized. Two
latest meta-analyses, including the recently published article by Qi et al., highlight the increased risk of severe
infections with EGFR-directed monoclonal antibodies. Further studies are needed to better identify the association
between EGFR-directed monoclonal antibody treatment and infection, as well as to elucidate the mechanism of
this toxicity and to develop tools to identify patients at increased risk for these complications. In the meantime,
awareness of the role of EGFR-directed antibodies in increased infection risk may have implications for dose
modification strategies in both clinical trial design and the practice of oncology.
Please see related article: http://www.biomedcentral.com/1741-7015/12/203.
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Monoclonal antibodies targeted to human epidermal
growth factor receptor (HER) family members, such as
the epidermal growth factor receptor (EGFR) and HER-2,
are widely used in the management of patients with solid
tumors. Trastuzumab and pertuzumab have significantly
improved outcomes for patients with HER-2 amplified
breast cancer [1], while the EGFR-directed antibody ce-
tuximab improves response and survival in patients
with head and neck cancer [2-4] and cetuximab and the
EGFR-directed antibody panitumumab prolong survival
in selected patients with colorectal cancer [5,6]. Recog-
nized toxicities of trastuzumab have included cardiac
dysfunction, diarrhea, and infusion reactions, whilst hy-
pomagnesemia [2], rash [7], and hypersensitivity reactions
[8] have been reported for cetuximab. Until recently,
the infections observed during treatment with EGFR-
or HER-2-directed antibodies had not been attributed
to the administration of the antibodies themselves. How-
ever, meta-analyses and path-breaking preclinical studies* Correspondence: barbara.burtness@yale.edu
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immunity, now call for a reexamination of the evidence
and greater vigilance in future trials of these agents.
Risk of infection after EGFR-directed antibody
therapy
Qi et al. [9] have recently published a meta-analysis in
BMC Medicine on the incidence and risk of severe infec-
tions in cancer patients treated with EGFR-directed an-
tibody therapy. Their analysis of 14,066 patients in 26
randomized controlled trials demonstrates an increased
risk for severe infection, with a hazard ratio (HR) of 1.34
(95% CI: 1.10–1.62, P = 0.003), and a numerical but not
statistically significant increase in fatal infections [9]. This
effect was most readily determined in the cancers for
which EGFR-directed antibody therapy is most common,
colorectal cancer, head and neck cancer, and non-small
cell lung cancer, perhaps reflecting greater power in these
analyses. The early recognition of an increased incidence
of neutropenia in E5397, a randomized trial of cisplatin/
placebo or cisplatin/cetuximab, was seemingly explained
by the greater exposure to cytotoxic chemotherapy in pa-
tients on the cetuximab arm [2]. In that trial, neutropeniaentral. This is an Open Access article distributed under the terms of the Creative
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(P = 0.04), but the number of treatment cycles was associ-
ated with risk of hematologic toxicity and the difference
between the arms was not significant when duration of
chemotherapy exposure was controlled for. The current
study undertook a meta-regression analysis to address the
possibility that increased infection resulted when better
anticancer efficacy prolonged the duration of exposure to
both the EGFR inhibitor and chemotherapy, and found
that longer duration of therapy actually predicted for a sig-
nificantly lower risk of severe infection.
The findings of Qi et al. [9] align well with two other
recent meta-analyses which also demonstrate an increase
in the risk of infection after HER family-directed an-
tibodies. Funakoshi et al. [10] also undertook a meta-
analysis of trials with cetuximab or panitumumab in
solid tumor patients. Their analysis included 14,957 pa-
tients in 28 randomized controlled trials; interestingly,
the two meta-analyses include an overlapping but not
identical set of trials, and thus may be seen as confirma-
tory of each other. There are 17 trials included in both
analyses, with an additional 9 included only in the Qi
paper [9], and an additional 11 only in the Funakoshi
paper [10]. The current paper includes several trials in
which dual targeted therapy is tested, e.g., bevacizumab
plus cetuximab or bortezomib plus cetuximab, which
may introduce as yet undefined effects from other tar-
geted therapies; however, the negative sensitivity analysis
is reassuring that the effect is not largely a reflection of
targeted agents other than EGFR-directed antibodies.
Confirmatory data also come from trials with unapproved
agents, as these were excluded from both the Qi and
Funakoshi analyses, but similar effects have been de-
scribed, including a 14% rate of infection after therapy
with the humanized anti-EGFR-antibody zalutumumab
[11,12]. Additionally, Funakoshi et al. [13] have des-
cribed an increased risk of high grade infection (HR,
1.21) and febrile neutropenia (HR, 1.28) in a meta-
analysis of 10,094 patients in 13 randomized controlled
trials of the HER2-directed antibodies trastuzumab and/or
pertuzumab [13].
The mechanism of action for this effect has not been
established; however, recent studies demonstrating a role
for EGFR in regulation of innate immunity suggest that
down-regulation of EGFR-dependent signaling in normal
tissues may explain an increase in severe infection. Host
cells are equipped with cellular sensors which detect
specific microbial components and activate cellular an-
timicrobial response. Toll-like receptors (TLRs) are an
important class of such sensors, expressed in macro-
phages and dendritic cells. Activation of TLR-dependent
signaling results in the synthesis of protective antimicro-
bial molecules such as interferon [14]. TLR-3 requires
tyrosine phosphorylation to recruit adaptor proteins, andthis process has recently been described to depend on
EGFR activation and Src binding [14]; inhibition of EGFR
was demonstrated to permit increased viral replication.
Dysregulated EGFR function in normal respiratory epithe-
lium and dendritic cells could thus be implicated in the
increased risk of severe infection following cetuximab,
panitumumab, or zalutumumab therapy, and may also
explain excess fulminant infections when EGFR inhibition
is added to mTOR inhibition in attempted synthetic lethal
cancer therapy, as described in several clinical trials [15].
Conclusions
Further preclinical studies to determine the role EGFR
signaling plays in innate immunity will be of interest. In
the meantime, awareness that EGFR-directed antibodies
increase infection risk mandates greater caution when
administering these agents in patients with active in-
fection, and has implications for the monitoring, dose
modification schemes, and correlative trials which are
appropriate to future trials with these agents. Moreover,
synthetic lethal drug combinations will need to be evalu-
ated carefully for the possibility of additive or synergistic
effects in suppression of innate immunity when EGFR
inhibitors are in the mix.
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